Venture Partners Viii, Llca... Net Worth

The estimated Net Worth of Venture Partners Viii, Llca... is at least $42.3 Milion dollars as of 2 November 2018. Venture Llca owns over 75,000 units of Twist Bioscience Corp stock worth over $42,325,917 and over the last 6 years Venture sold TWST stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Llca TWST stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Twist Bioscience Corp stock since 2018, according to the Form 4 filled with the SEC. Most recently Venture bought 75,000 units of TWST stock worth $1,050,000 on 2 November 2018.

The largest trade Venture's ever made was buying 75,000 units of Twist Bioscience Corp stock on 2 November 2018 worth over $1,050,000. On average, Venture trades about 75,000 units every 0 days since 2018. As of 2 November 2018 Venture still owns at least 954,146 units of Twist Bioscience Corp stock.

You can see the complete history of Venture Llca stock trades at the bottom of the page.

Insiders trading at Twist Bioscience Corp

Over the last 6 years, insiders at Twist Bioscience Corp have traded over $141,837,821 worth of Twist Bioscience Corp stock and bought 168,550 units worth $2,482,088 . The most active insiders traders include Fred B Craves, Keith Crandell oraz Emily M. Leproust. On average, Twist Bioscience Corp executives and independent directors trade stock every 8 days with the average trade being worth of $465,824. The most recent stock trade was executed by Dennis Cho on 6 September 2024, trading 275 units of TWST stock currently worth $10,769.

What does Twist Bioscience Corp do?

at twist bioscience, our expertise is synthetic dna. we have developed a proprietary semiconductor-based synthetic dna manufacturing process featuring a 10,000-well silicon platform capable of producing synthetic biology tools, such as oligonucleotides, genes, pathways, chassis and genomes. by synthesizing dna on silicon instead of on traditional 96-well plastic plates, our platform overcomes the current inefficiencies of synthetic dna production, and enables cost-effective, rapid, high-quality and high throughput synthetic gene production. the twist bioscience platform has the potential to greatly accelerate the development of personalized medicine, sustainable chemical production, improved agriculture production as well as new applications such as in vivo diagnostics, biodetection and data storage. for more information, please visit www.twistbioscience.com .

Complete history of Venture Llca stock trades at Twist Bioscience Corp

Twist Bioscience Corp executives and stock owners

Twist Bioscience Corp executives and other stock owners filed with the SEC include:

• Emily Leproust,
  Chairman of the Board, President, Chief Executive Officer
• James Thorburn,
  Chief Financial Officer
• Patrick Finn,
  Chief Commercial Officer
• Dr. Emily Marine Leproust Ph.D.,
  Co-Founder, Chairman, Pres & CEO
• Patrick Weiss,
  Chief Operating Officer
• James M. Thorburn,
  Chief Financial Officer
• Dr. Patrick John Finn Ph.D.,
  Chief Commercial Officer
• Mark Daniels,
  Senior Vice President, Chief Legal Officer, Chief Ethics and Compliance Officer and Secretary
• Dr. William Charles Banyai Ph.D.,
  Sr. VP of Advanced Devel., GM of Data Storage & Director
• Jan Johannessen,
  Independent Director
• Nelson Chan,
  Independent Director
• Robert Ragusa,
  Independent Director
• Keith Crandell,
  Independent Director
• Robert Chess,
  Lead Independent Director
• Xiaoying Mai,
  Independent Director
• Nicolas Barthelemy,
  Independent Director
• William Banyai,
  Director
• Paula Green,
  Vice President of Human Resources
• Bill Peck,
  Chief Technology Officer
• Erin Smith,
  Senior Vice President - Government affairs and Public policy
• Martin Kunz,
  Senior Vice President - Operation
• Patrick Weiss,
  Chief Operating Officer
• Tracey Mullen M.B.A.,
  Sr. VP of Operations
• Paula Green,
  Sr. VP of HR
• Dennis Cho,
  Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer
• Kevin B. Yankton,
  VP & Chief Accounting Officer
• Mark Daniels Esq.,
  Sr. VP, Chief Legal Officer, Chief Ethics & Compliance Officer and Sec.
• Dr. Aaron K. Sato,
  Chief Scientific Officer & Chief Scientific Officer of BioPharma
• Siyuan Chen,
  Chief Technology Officer
• Adam Laponis,
  Chief Financial Officer
• Alpha Fund L.P. Ever,
  10% owner
• Fred B Craves,
  Director
• Venture Partners Viii, Llca...,
  
• Melissa A. Starovasnik,
  
• Dennis Cho,
  See Remarks
• Kevin Bruce Yankton,
  Chief Accounting Officer
• Robert F. Werner,
  Chief Accounting Officer